Skip to content
Palanor is in early release, with our founding customers.Become a founding customer →
The Real Rate Index45.30.00Palanor: Inflation Pulse50.7+0.09Palanor: Geopolitical Stress60.0-2.16Palanor: Liquidity57.9-0.79Palanor: Capital Tightness47.5+0.91Palanor: Industrial Pulse70.10.00Palanor: AI Margin Compression53.4+0.29Palanor: Consumer Confidence48.6+0.50Palanor: US Dollar Strength46.50.00Palanor: Labor Heat63.2-0.01Palanor: Recession Vocabulary28.1+0.54Palanor: Uncertainty Index53.4+1.24Palanor: US Jobs Health40.30.00Palanor: Energy Transition37.0-0.52Palanor: Reshoring Sentiment22.8+0.54Palanor: AI Substitution28.4-0.24The Social Fabric Index45.70.00Palanor: Geopolitical Anxiety19.4-0.45Palanor: Quit Pressure37.6+0.42The Mania Index88.00.00The Palanor Index57.1-0.51Cost Disease Spread33.20.00Palanor: US vs China49.5-0.17Rise of Socialism Index40.8-0.26The Bubble Memory79.90.00Palanor: Steward Confidence50.8+0.13The Long Watch90.30.00The Reshoring Index55.2+0.00The Capital Return Index81.0-0.75The Discourse Index72.4+1.83The Hesitation Index30.8-6.58Palanor AI Inference Cost Index71.2-0.03The AI Capex Race Index78.4+1.36The Boardroom Index82.5-0.00The Layoff Cycle Index32.8-2.51Capital Deployment Posture Index62.3+1.26The Consumer Health Index41.7-2.96Labor Hours Composite44.40.00The Dollar Erosion Index66.6+0.14Palanor: Risk Appetite36.2+0.83
PalanorPalanor

Company Dossier · Health Care

Viatris

VTRSNasdaqPharmaceuticalsWILMINGTON, US-DE, USLarge capWebsite ↗
  • S&P 500
  • Russell 1000

What Viatris is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.

Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →

The latest read

Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.

  • Revenue over the four quarters to June 30, 2026: $14.7 billion, up 4.4% from a year earlier.SEC EDGAR filings (XBRL)
  • Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $1.95 billion, up 11% from a year earlier.SEC EDGAR filings (XBRL)
  • Capital expenditure over the four quarters to June 30, 2026: $0.38 billion, up 23% from a year earlier.SEC EDGAR filings (XBRL)
  • Share buybacks in the fiscal year to December 31, 2025: $0.50 billion.SEC EDGAR filings (10-K)
  • Latest earnings call or results release (August 6, 2026): sentiment 0.70 on a −1 to +1 scale (confident, opportunity-framed), confidence 0.80 of 1.Palanor Discourse
  • Guidance in the last 90 days: 4 outlook figures raised, 0 lowered, 1 held.Guidance Ledger (8-K results releases)
  • Latest annual report (filed February 26, 2026): 3 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
  • Insiders were net sellers in Q2 2026: $0.8 million on the open market.SEC Form 4
  • 1,033 institutional managers reported a position at June 30, 2026 (+5 on the quarter before).SEC Form 13F
  • H-1B filings certified in Q2 2026: 11 (6 a year earlier).U.S. Department of Labor (OFLC)

Company Posture

How Company Posture is measured →

What Viatris is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.

Steady · Confident

Expanding ↔ Retrenching

Steady

RetrenchingExpanding

Confident ↔ Hedging

Confident

HedgingConfident

Pressure

Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).

Credit

How these are built →

Viatris's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.

Debt on the balance sheet

$13.3B

  • Due within a year $1.7B
  • Longer term $11.6B
  • Default point $7.5B (short + ½ long)

Finance leases included · Jun 30, 2026 filing

Bonds priced, last 12 months

None

U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.

PricedAmountCouponMaturesSpreadYield
Jun 12, 2026€650M4.250%2033 (7y)+145bp4.294%

From the pricing term sheets Viatris filed with the SEC. Spread is to the benchmark Treasury (or Bund, Gilt) at pricing.

Charts

Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.

Cash flow

Business

Viatris: free cash flow, trailing twelve months

Operating cash flow minus capital expenditure, $ billions, from SEC filings

$2.0BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: operating cash flow and capital expenditure

Trailing twelve months, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: revenue, trailing twelve months

$ billions, from SEC filings

$14.7BData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Capital returned and raised

Business

Viatris: share buybacks by fiscal year

Cash paid to repurchase common stock, $ billions, from the 10-K

$0.50BData to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: debt issued and repaid by fiscal year

Long-term debt, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: debt maturity schedule, latest annual report

Scheduled repayments of long-term debt principal by year from the fiscal year end, $ billions, from the 10-K

Data to Dec 2025
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: debt due within a year and cash

At each balance-sheet date, $ billions, from SEC filings

Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: interest coverage

Operating income ÷ interest expense, trailing twelve months, from SEC filings

−0.2Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

What the company says

Business

Viatris: guidance raised minus lowered

Guidance Ledger statements by quarter

4.0Data 23 days ago
ImageDataGuidance Ledger by Palanor · source: SEC EDGAR
Business

Viatris: earnings call sentiment

Palanor Discourse score per call, −1 to +1

0.70Data to Aug 2026
ImageDataPalanor calculation
Business

Viatris: earnings call confidence

Palanor Discourse score per call, 0 to 1

0.80Data to Aug 2026
ImageDataPalanor calculation
Business

Viatris: risk factors added per annual report

New Item 1A risk factors in each 10-K

3.0Data to Feb 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

Hiring and ownership

Business

Viatris: H-1B filings certified

Labor Condition Applications by quarter received

11.0Data to Jun 2026
ImageDataU.S. Department of Labor, Office of Foreign Labor Certification disclosure data, dol.gov
Business

Viatris: insider net buying

Open-market purchases minus sales by officers and directors, $ millions, by quarter

−$0.8MData to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR
Business

Viatris: institutional holders

Managers reporting a position on Form 13F, by quarter

1,033Data to Jun 2026
ImageDataU.S. Securities and Exchange Commission, EDGAR

In the news

Headlines that name Viatris, with the publisher and a link. The tone is read from each headline’s own words, never from a summary of the article.

30 days
2 headlines
50% positive · 0% negative
90 days
2 headlines
50% positive · 0% negative

Filings and records

The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.

  1. Oct 21, 2026Lobbying
    Lobbying report (VIATRIS INC.)third_quarter 2026 · $0.5 million
  2. Oct 19, 2026Lobbying
    Lobbying report (FEROX STRATEGIES)third_quarter 2026 · $0.1 million
  3. Oct 16, 2026Lobbying
    Lobbying report (S-3 GROUP)third_quarter 2026 · $0.1 million
  4. Oct 8, 20268-K
    Material agreement signedItem 1.01
  5. Oct 7, 2026Lobbying
    Lobbying report (HOLLAND & KNIGHT LLP)third_quarter 2026 · $0.1 million
  6. Sep 22, 2026Patent
    Patent granted: PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAMUS 12740988
  7. Aug 4, 2026Patent
    Patent granted: Methods of Using Meloxicam for Pain Treatment and ManagementUS 12697341
  8. Jul 21, 2026Lobbying
    Lobbying report (VIATRIS INC.)second_quarter 2026 · $0.4 million
  9. Jul 20, 2026Lobbying
    Lobbying report (FEROX STRATEGIES)second_quarter 2026 · $0.1 million
  10. Jul 17, 2026Lobbying
    Lobbying report (S-3 GROUP)second_quarter 2026 · $0.1 million
  11. Jul 14, 2026Patent
    Patent granted: Solid Oral Pharmaceutical Compositions Including Alkyl 3,4,5-Trihydroxybenzoate as a Nitrosamine InhibitorUS 12678420
  12. Jul 13, 2026Lobbying
    Lobbying report (HOLLAND & KNIGHT LLP)second_quarter 2026 · $0.1 million
  13. Jul 1, 20268-K
    Material agreement signedItem 1.01
  14. Jun 18, 20268-K
    Material agreement signedItem 1.01
  15. Jun 16, 2026Patent
    Patent granted: COMPOSITIONS AND USE OF VARENICLINE FOR TREATING DRY EYEUS 12653824
  16. Jun 9, 2026Patent
    Patent granted: PHARMACEUTICAL COMPOSITION COMPRISING MELOXICAMUS 12648912
  17. May 15, 20268-K
    Shareholder vote resultsItem 5.07
  18. May 4, 20268-K
    Director or officer changeItem 5.02
  19. Feb 26, 20268-K
    Exit or restructuring costsItem 2.05
  20. Feb 26, 202610-K
    Annual report (10-K)3 risk factors added, 0 removed
  21. Feb 3, 20268-K
    Director or officer changeItem 5.02
  22. Dec 5, 20258-K
    Director or officer changeItem 5.02
  23. Dec 5, 20258-K
    Shareholder vote resultsItem 5.07
  24. Aug 5, 20258-K
    Director or officer changeItem 5.02
  25. May 5, 20258-K
    Director or officer changeItem 5.02
  26. Feb 27, 202510-K
    Annual report (10-K)0 risk factors added, 1 removed
  27. Dec 6, 20248-K
    Director or officer changeItem 5.02
  28. Dec 6, 20248-K
    Shareholder vote resultsItem 5.07
  29. Feb 28, 202410-K
    Annual report (10-K)1 risk factors added, 1 removed

Peers

Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.

CompanyRevenueFree cash flowThrough
Zoetis ZTS$9.5B$2.3BJun 30, 2026
Organon & Co. OGN$6.1B$0.6BJun 30, 2026
Jazz Pharmaceuticals JAZZ$4.6B$1.6BJun 30, 2026
Bristol Myers Squibb BMY$49.2B$11.4BJun 30, 2026
Corcept Therapeutics CORT$0.8B$0.1BJun 30, 2026
BrightSpring Health Services BTSG$14.4B$0.4BJun 30, 2026
Labcorp LH$14.3B$1.2BJun 30, 2026
DaVita DVA$14.0B$1.6BJun 30, 2026

Identity

SEC CIK
1792044
LEI
254900ZZTSW7NL773X71
Wikidata
Q101983981
SAM UEI
NEYRLCN7HME7
SAM UEI
TZY5BKQHCF21

Built from SEC EDGAR filings (public domain), the Guidance and KPI Ledgers, Palanor Discourse, U.S. Department of Labor filings, USPTO, USAspending and Senate lobbying records, and rights-checked news headlines. Updated nightly; this page was built Oct 22, 2026. How the Dossier is built

S&P 500, S&P 100, S&P MidCap 400 and Dow Jones Industrial Average are trademarks of S&P Dow Jones Indices LLC or its affiliates; Nasdaq-100 is a trademark of Nasdaq, Inc.; Russell 1000 is a trademark of FTSE Russell. Membership is shown for identification only. Palanor is not affiliated with or endorsed by the index owners.

Cookies

We only use essential cookies to keep you signed in and remember your theme. No analytics, no tracking, no ads. See the Privacy Policy for the full read.